Methanethiosulfonate derivatives as ligands of the STAT3-SH2 domain

Elena Gabrielea, Chiara Ricci, Fiorella Meneghetti, Nicola Ferri, Akira Asaid and Anna Sparatore

ABSTRACT
With the aim to discover new STAT3 direct inhibitors, potentially useful as anticancer agents, a set of methanethiosulfonate drug hybrids were synthesized. The in vitro tests showed that all the thiosulfonic compounds were able to strongly and selectively bind STAT3-SH2 domain, whereas the parent drugs were completely devoid of this ability. In addition, some of them showed a moderate antiproliferative activity on HCT-116 cancer cell line. These results suggest that methanethiosulfonate moiety can be considered a useful scaffold in the preparation of new direct STAT3 inhibitors. Interestingly, an unusual kind of organo-sulfur derivative, endowed with valuable antiproliferative activity, was occasionally isolated.

Introduction
Signal transducer and activator of transcription 3 (STAT3) were identified in 1994 as a DNA-binding factor that selectively interacts with IL-6-responsive element in the promoter of acute-phase genes from IL-6-stimulated hepatocytes. It belongs to STAT family, latent cytoplasmic transcription factors that are activated in response to extracellular signals such as cytokines, growth factors, and hormones. STATs directly transmit signals from plasma membrane to the nucleus and regulate cell growth and survival by modulating the expression of specific target genes. This family comprises seven isoforms, namely STAT1 to STAT4, STAT5a, STAT5b, and STAT6, that present several structurally and functionally conserved domains including the Src homology 2 (SH2) domain which is essential for the activation cascade pathway. Upon phosphorylation in the cytoplasm, STAT3 can dimerize forming homodimers or heterodimers through specific reciprocal SH2-phosphotyrosine interaction; the dimers then translocate into the nucleus, bind to specific DNA-binding elements, and activate transcription of target genes, which are mainly involved in cell proliferation, differentiation, apoptosis, and inflammation.

In addition, STAT3 was found to be constitutively activated by aberrant upstream tyrosine kinase activity in a broad spectrum of cancer cell lines and human tumors, and therefore it is considered a promising target for cancer therapy. Several studies confirmed that STAT3 inhibitors have minimal effects on normal cells, thus providing the potential for selective tumor cell elimination.

Two main approaches have been explored to inhibit STAT3 signaling: direct, by interaction of small molecules with the protein and indirect, inhibiting the upstream tyrosine kinases that are responsible for STAT3 activation or blocking factors as JAK, Src, Bcr-Abl, FLT3, and EGFR that are involved in the activation of STAT3 signaling. This kind of inhibition induces tumor-cell apoptosis but it is poor selective.

Direct inhibitors should be preferred because the nonspecific mechanism of action of indirect inhibitors could cause important adverse effects. In the direct approach, much of the efforts have been addressed at disrupting the STAT3:STAT3 dimerization, which is a fundamental step in STAT3 activation. The slow progress of obtaining suitable direct STAT3 inhibitors for preclinical investigation and for clinical development could be attributed to the challenge of targeting protein-protein interactions (PPIs), which are very different from those of more-established targets such as enzymes and G-protein-coupled receptors. Nonetheless, a number of successful examples started to prove that it is possible to overcome these hurdles and develop PPI modulators as drugs.

Recently, a number of small molecule compounds which directly inhibit the activity and function of STAT3 have been discovered and studied for cancer treatment and prevention.

Among them, S3I-201 (Figure 1) has been identified as a selective STAT3-SH2 domain inhibitor, which blocked the formation of STAT3 homodimers (IC50 = 86 μM) and inhibited the proliferation of breast and hepatocellular cancer cells in mice. However, the presence of an electrophilic tosylate leaving group in S3I-201 renders it highly susceptible to alkylation also other substrates, and therefore it is not very stable in the biological medium. Further studies lead to the synthesis of several analogs of S3I-201, able to bind the SH2 domain with higher affinity.
It is well known from literature that S-methyl methanethiosulfonate (SMMTS), isolated from cauliflower, is able to inhibit colon tumor incidence when administered to rats during the post-initiation phase of carcinogenesis.

Recently, we have synthesized and studied two methanethiosulfonate (MTS) derivatives (1 and 2; Figure 2) of valproic acid (VA) endowed with interesting anticancer properties. In particular, compound 1 exhibited in vitro antiproliferative activity at micromolar concentration on different tumor cell lines and in vivo inhibited the growth of PC3 in subcutaneous xenografts.

Although SMMTS and other MTS derivatives exert their chemopreventive and anticancer activity through multiple mechanism, their hypothetical direct or indirect activity on STAT3 had not been investigated yet. For this reason, to evaluate their ability to interact with STAT3-SH2 domain, we submitted compounds 1 and 2 to the AlphaScreen-based assay, an in vitro competitive binding test used to identify compounds able to directly inhibit the binding of SH2-containing proteins to their correspondent phosphopeptides, the physiological ligands.

Since both compounds showed a potent inhibition of the binding between STAT3-SH2 domain and its phosphopeptidic ligand, we decided to extend this investigation to other thiosulfonate-drug hybrids (Figure 2), as well as to their parent compounds, with the aim to better understand and confirm the behavior of the thiosulfonate moiety toward this protein.

NSAIDs-thiosulfonate hybrids 3, 4, and 5, which are derivatives of sulindac, acetyl salicylic acid (ASA), and diclofenac, respectively, have been chosen because it is known that COX inhibitors are useful in the treatment of certain kind of tumors. The idea was that the combination of COX inhibition with the anticancer properties of thiosulfonates could lead to a new chemical entity where the two components act in a synergistic way against cancer development.

The anticancer activity of NSAIDs seems also related to additional mechanisms. Indeed, ASA induced apoptosis in colorectal cancer (CRC) cells in aspirin-treated mice or in human glioblastoma cell line A172 via downregulation of IL-6-dependent STAT3 signaling suggesting that aspirin could be useful for a potential anti-glioblastoma or anti-CRC therapeutic approach. Also sulindac treatment exerted a significant time-dependent cell growth-inhibitory effect on oral squamous cell carcinoma (SCCa) cells inducing a STAT3 down-modulation. Since the above-mentioned activities seem to be related to the downregulation of STAT3 pathway and not to a direct interaction with the STAT3-SH2 domain, we thought that the linkage of a NSAID drug with a direct STAT3 inhibitor, such as a thiosulfonate derivative, could be a useful strategy to obtain a more powerful STAT3 inhibitor.

In addition, we decided to modify the structure of compound S3I-201 through the replacement of the oxygen with a sulfur atom, thus obtaining compound 6 (Figure 1) or through the replacement of the tosylate group with the methanethiosulfonate (compound 7, Figure 1). The aim was to evaluate if the presence of the thiosulfonate moiety can modify both the ability of S3I-201 to interact with STAT3 and its potency as antiproliferative agent. Actually, compound 7 was not obtained, and compound 8 was instead isolated.

**Materials and methods**

**General**

All commercially available solvents and reagents were used without further purification, unless otherwise stated. Reactions monitored by thin-layer chromatography (TLC) analysis on aluminum-backed Silica Gel 60 plates (70–230 mesh, Merck). CC = flash column chromatography (Geduran Si 60, 40–63 μm, Merck). 1H- and 13C NMR and HRMS: FT-Orbitrap mass spectrometer in positive/
negative electro spray ionization (ESI). Melting points: Büchi Melting Point B540 instrument, uncorrected.

**Synthesis of hybrid compounds (1), (2) and (5)**

2-((Methylsulfonyl)thio)ethyl 2-propylpentaanoate (1), S-(2-(2-propylpentanamido)ethyl) methanesulfonothioate (2) and 2-((methylsulfonyl)thio)ethyl 2-(2-((2,6-dichlorophenyl)amino)phenyl)acetate (5) were prepared according to the literature procedures 17, 24.

**(Z)-5-fluoro-2-methyl-1-[(4-(methylsulfonyl)phenyl)iminenylo]-1H-indene-3-acetic acid 2-methanesulfonylfuranylethyl ester (3) and 2-acetoxybenzoic acid 2-methanesulfonylfuranylethyl ester (4)**

**General method**

A 1 N solution of dicyclocexlycarbodiimide (DCC, 4.22 ml) in CH2Cl2 (67 ml) was added to a solution of 2-(2-hydroxyethyl) methanesulfonothioate 25 (9; 3.84 mmol), 4-dimethylaminopyridine (DMAP, 252 mg, 2.15 mmol) and sulindac or acetyl salicylic acid (3.84 mmol) in DMF (7.5 ml) under nitrogen. The two compounds have been already described in two patents 26, 27, and their characterization is now integrated.

The two compounds have been already described in two patents 26, 27, and their characterization is now integrated.

**(Z)-5-fluoro-2-methyl-1-[(4-(methylsulfonyl)phenyl)iminenylo]-1H-indene-3-acetic acid 2-methanesulfonylfuranylethyl ester (3)** 26

CC (CH2Cl2/MeOH, 99:5:0.5). Yield 80%; mp 118.5–119.5 °C. 1H NMR (300 MHz, CDCl3): δ 7.70 (dd, 4H, Ar-CH2-CO); 7.20 (s, 1H, Ar-CH2-CO); 7.18 (d, 1H, Ar=H); 7.18 (d, 1H, Ar=H); 6.85 (1H, Ar=H); 6.56 (t, 1H, C=CH2); 4.40 (t, 2H, OCH2); 3.60 (s, 2H, Ar-CH2-CO2); 3.40 (t, 2H, CH2-S); 3.30 (s, 3H, SO2-CH3); 2.80 (s, 3H, SO-CH3); 2.20 (s, 3H, -CH3).

**2-Acetoxybenzoic acid 2-methanesulfonylfuranylethyl ester (4)** 27

CC (cyclohexane/EtOAc, in gradient from 80:20 to 60:40). Yield 28%; mp 90.5–91.5 °C. 1H NMR (300 MHz, CDCl3): δ 8.00 (d, 1H, Ar-H); 7.60 (t, 1H, Ar-H); 7.30 (t, 1H, Ar-H); 7.10 (d, 1H, Ar-H); 4.60 (t, 2H, COO-CH2); 3.50 (t, 2H, CH2-S); 3.40 (s, 3H, SO2-CH3); 2.40 (s, 3H, OCO-CH3).

**2-(Methylsulfonyl)thio)acetic acid (15)**

Sodium methanesulfonate (13: 500 mg, 3.73 mmol) and 2-bromoacetic acid (14: 470 mg, 3.38 mmol) were mixed together in acetone (8 ml). The reaction was stirred at room temperature for 20h and was monitored by TLC. After the completion of reaction, inorganic salts were filtered and the solution was evaporated under reduced pressure. The resulting yellow pale oil was crystallized with CH2Cl2 to provide the final product as a white crystal solid. Yield 80%; mp 80.1–81.5 °C (Lit. 95–96°) 28. 1H NMR (300 MHz, DMSO-d6): δ 13.18 (br s, 1H, -COOH collapsed with D2O), 4.07 (s, 2H, -COOH), 3.53 (s, 3H, -CH3). ppm

**2-Hydroxy-4-(2-(tosylthio)acetamido)benzoic acid (6)**

Sodium tolenethiosulfonate 29 (12: 812 mg, 3.83 mmol) and 4-(2-chloroacetamido)-2-hydroxybenzoic acid 30 (11: 805 mg, 3.48 mmol) were dissolved in anhydrous DMF (7.5 ml) under nitrogen. The reaction was stirred at 60 °C for 4h and was monitored by TLC. After cooling at room temperature, inorganic salts were filtered and the solution was evaporated under reduced pressure. The obtained residue was dried with CH2Cl2 and washed with cold water three times and then with iced brine. The organic layer was dried with anhydrous Na2SO4 filtered and evaporated under reduced pressure to dryness to provide a residue that was purified by CC (silica gel; CH2Cl2/MeOH; in gradient), using the Flash Chromatography Purification System Biotage SP-1; the product eluted with 1.3% of MeOH. A salmon pink solid was obtained. The solid was rinsed first with ethyl ether/petroleum ether (2:1) and then with ethyl ether/MeOH (1:0.2) to give the final product as a white solid. Yield 60%; mp 170.0–171.9 °C. 1H NMR (300 MHz, DMSO-d6): δ 11.41 (br s, 1H, -OH collapsed with D2O), 10.42 (s, 1H, -NH- collapsed with D2O), 7.80 (d, 2H, J=7.8 Hz, Ar-H); 7.71 (d, 1H, J=8.8 Hz, Ar-H); 7.38 (d, 2H, J=7.8 Hz, Ar-H); 7.11 (d, 1H, J=1.6 Hz, Ar-H); 6.91 (dd, 1H, J1=1.6 Hz, J2=8.8 Hz, Ar-H); 4.05 (s, 2H, -CH2-S); 2.31 (s, 3H, Ar-CH3). Other peaks: 382.04190; found: 382.04130.

**S-(methylsulfonyl)ethyl 4-amino-2-hydroxybenzotheioate (8)**

To a solution of 2-(methylsulfonyl)thio)acetic acid (15: 366 mg, 2.15 mmol) in anhydrous DMF (2 ml) under argon and at 0 °C, hydroxybenzotriazole (HOBt, 290 mg, 2.15 mmol), N,N-disopropylethylamine (DIPEA, 0.341 ml, 1.96 mmol), and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC-HCl, 412 mg, 2.15 mmol) were added. After 5-min p-aminoalicylic acid (300 mg, 1.96 mmol) was added, and the reaction was stirred at room temperature for 6h. The reaction was monitored by TLC. After the completion of reaction, the solution was evaporated under reduced pressure. The obtained residue was diluted with EtOAc and washed first with a cold solution of 0.5 N HCl and then with cold brine. The organic layer was dried with anhydrous Na2SO4 filtered, and evaporated under reduced pressure to dryness, and the crude product was then purified by CC (silica gel; CH2Cl2/MeOH; in gradient); the product eluted with 0.3% of MeOH. After washing with diethyl ether, a white solid was obtained. Yield 6%; mp 199.6–202.3 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.67 (br s, 1H, -OH collapsed with D2O), 7.51 (d, 1H, J=8.7 Hz, Ar-H); 6.43 (br s, 2H, NH2 collapsed with D2O), 6.17 (dd, 1H, J1=2.1 Hz and J2=8.7 Hz, Ar-H); 6.01 (d, 1H, J=2.1 Hz, Ar-H), 4.66 (s, 2H, S-CH2-SO2); 2.98 (s, 3H, SO2-CH3) ppm. 13C NMR (75 MHz, DMSO-d6): δ 171.93, 165.09, 162.41, 145.56, 145.01, 141.48, 131.47, 130.47, 127.31, 110.67, 108.53, 106.59, 21.44 ppm. HRMS (ESI): m/z calcd for C11H8NO5S2 [M+H]+: 284.02190; found: 284.02410.
The positions of hydrogen atoms were introduced by a close examination of a final difference Fourier.

These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Center, 12, Union Road, Cambridge CB21EZ, UK; fax: +44 1223 336 033; or deposit@ccdc.cam.ac.uk). CCDC-1495448 contains the supplementary crystallographic data for this paper.

**Crystal data for (8)**

C₉H₁₁NO₄S₂, Mᵣ = 261.3 g/mol, Triclinic, Space group P-1, a = 5.080(3) Å, b = 9.8552(6) Å, c = 11.4649(7) Å, α = 81.569(1), β = 88.232(1), γ = 77.411(1), V = 554.12(6) Å³, Z = 2, Dcalc = 1.566 Mg/m³, R = 0.033 (5853 reflections), wR = 0.0864, T = 293(2)K, GOF = 1.080. The reflections were collected in the range 1.8° ≤ θ ≤ 25.02° employing a 0.55 × 0.22 × 0.02 mm crystal.

**AlphaScreen-based assay**

STAT3 inhibitory activity of the described compounds was tested by the AlphaScreen-based assay to evaluate the potential inhibition of the interaction between STAT3-SH2 domain and pTyr-containing peptides according to the previously reported procedure. For the most interesting compounds, selectivity tests versus STAT1 and Grb2 (Growth factor receptor-bound protein 2) were performed. AlphaScreen is a bead-based nonradioactive assay system for detecting biomolecular interactions in a microtiter plate format. Binding of biological partners brings donor and acceptor beads into close proximity and as result, a luminescent signal between donor and acceptor beads simultaneously before detection at 570 nm using EnVisionXcite (Perkin Elmer, Waltham, MA). These data were collected in the range 1.8° ≤ θ ≤ 25.02° employing a 0.55 × 0.22 × 0.02 mm crystal.

**Results and discussion**

**Synthesis**

Compounds 1, 2, and 5 were prepared through coupling reactions between valproic acid and S-(2-hydroxyethyl) methanesulfonothioate (9) or S-(2-aminoethyl) methanesulfonothioate (10) or between diclofenac and 9, respectively as previously described. A similar synthetic route was used for the synthesis of 3 and 4 as indicated in Scheme 1.

**Scheme 1.** Reagents and conditions: (a) DCC, DMAP, CH₂Cl₂, rt, 1.5 h.

**MTT assay**

After 48 h of treatment, medium was removed from each well, and cells were incubated with fresh medium, containing 10% (v/v) of MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) reagent. MTT, by interacting with vital cells mitochondria, is converted to formazan, with the development of visible purple crystals. After dissolving these crystals with isopropanol-HCl, the quantification of the conversion of MTT to formazan is determined through spectrophotometer analysis (595 nm), as previously described.

**Cell culture**

The colorectal cancer HCT116 cells were cultured in McCoy’s media supplemented with penicillin (10,000 U/ml), streptomycin (10 mg/ml), nonessential amino acid, and 10% fetal calf serum (FCS). Cells were then seeded in 48 well plates and, after 24 h, they were incubated with different concentration of newly synthesized compounds dissolved in DMSO. The same volume of solvent was added to control conditions and did not exceed 0.5% (v/v).
ORTEP\textsuperscript{34} drawing is shown in Figure 3. In the molecule, the central -S-C=O moiety is approximately coplanar with respect to the p-aminosalicylic system, which presents a strong intramolecular O-H\ldots O hydrogen bond. The conformation of the lateral chain is characterized by a torsion angle C7-S2-C8-S1 of 36(1)°. In the crystal, molecules are linked by N-H\ldots O hydrogen-bonding interactions, forming chains parallel to the b-axis direction.

**Biological results**

The thiosulfonate-drug hybrids 1–5, the S3I-201 analog 6 and compound 8, together with their parent compounds have been submitted to the AlphaScreen-based assay, to investigate their ability to directly bind STAT3-SH2 domain.

Moreover, in order to check the selectivity of our molecules on STAT3, other SH2-containing proteins, such as STAT1 and Gbr2 (Growth factor receptor-bound protein 2), highly homolog to STAT3 (78% and 65%, respectively), have also been tested. Results, expressed as % of protein inhibition at 30 and 3 \mu{M} concentration or as IC\textsubscript{50} (\mu{M}), are reported in Table 1. In addition, the cytotoxicity\textsuperscript{35} of these compounds on HCT-116 cell line (a human colon carcinoma cell line which expresses high levels of STAT3\textsuperscript{38}) was also tested. The inhibitory activities (IC\textsubscript{50} \mu{M} values) are also listed in Table 1.

The obtained results indicate that all thiosulfonate hybrids are able to strongly and selectively bind STAT3-SH2 domain, whereas the parent drugs were completely devoid of this activity at the highest concentration tested (30 \mu{M}). Although NSAIDs such as acetylsalicylic acid and sulindac are reported to induce STAT3 downregulation\textsuperscript{22,23}, these results indicate that these drugs are not able to directly bind to the SH2 domain of the protein. Even the thiosulfonic parent compounds 9 and 10\textsuperscript{17} lower inhibited STAT3 compared to their corresponding drug hybrids, possibly for their higher hydrophilicity or too small size. Indeed, small methanethiosulfonate derivatives have been previously used to examine the accessibility of cysteine residues in ion channel and receptor proteins\textsuperscript{39–42}, because these reagents can react with the free thiol group of cysteine residues to form a mixed disulfide between the cysteine sulfur and the electrophilic moiety of the reagent. Of course, if the cysteine residue is in a critical region, the additional

\[\text{Scheme 2. Reagents and conditions: (a) anh. DMF, N}_2, 60 \text{ °C, 4 h.}\]

\[\text{Scheme 3. Reagents and conditions: (a) acetone, rt, 20 h; 80%. (b) HOBt, EDC-HCl, DIPEA, anh. DMF, Ar, 0 \text{ °C to rt, 5 h; 6%.}\]

\[\text{Figure 3. Left: ORTEP}\textsuperscript{34} \text{ drawing of 8, showing the arbitrary atomic numbering (displacement ellipsoids at 40% probability). Right: Intermolecular interactions viewed about along a-axis.}\]
Table 1. Comparative SH2 domain inhibitory activity and cytotoxicity on HCT-116 cell line of the tested compounds.

| Compound | % Inhibition STAT3 | IC50 (µM) ± SD | % Inhibition STAT1 | IC50 (µM) ± SD | % Inhibition Grb2 | IC50 (µM) ± SD |
|----------|-------------------|--------------|-------------------|--------------|-----------------|--------------|
|          | % Inhibition      |              |                   |              |                 |              |
|          | 30 µM            | 3 µM         |                   | 30 µM        | 3 µM            | 3 µM         |
| 1        | 101.7±0.7         | 101.2±2.2    | 0.7±0.1           | n.t.         | 44.9±10.5       | >3           |
| 2        | 105.8±0.3         | 67.2±11.0    | 1.4±0.1           | n.t.         | 1.9±2.2         | >3           |
| 3        | 101.8±0.4         | 105.2±8.2    | 0.5±0.1           | n.t.         | 46.7±1.1        | >3           |
| 4        | 100.0±0.1         | 93.5±2.6     | 1.4±0.1           | n.t.         | 44.2±0.8        | 3.6±0.0      |
| 5        | 101.8±0.2         | 110.5±2.2    | 0.5±0.2           | n.t.         | 35.4±2.1        | >3           |
| 6        | 58.4±1.1          | 46.0±0.8     | 4.9±0.4           | n.t.         | 18.0±0.2        | >3           |
| 8        | 41.8±0.9          | n.t.         | >30               | n.t.         | n.t.            | n.t.         |
| VA       | 0.2±3.2           | n.t.         | >30               | 2.7±3.0      | n.t.            | >30          |
| Sulindac | 4.2±3.2           | n.t.         | >30               | 4.9±2.0      | n.t.            | >30          |
| ASA      | 3.8±1.9           | n.t.         | >30               | 6.3±1.7      | n.t.            | >30          |
| Diclofenac sodium salt | 4.5±2.4 | n.t.         | >30               | 6.5±2.1      | n.t.            | >30          |
| 9        | 11.6±0.5          | n.t.         | >30               | n.t.         | n.t.            | n.t.         |
| 10       | –10.2±0.2         | 46.8±10.1    | >3                | n.t.         | 14.5±7.1        | >3           |
| 15       | n.t.              | n.t.         | n.t.              | n.t.         | n.t.            | n.t.         |
| S3I-201  | 7.2±1.7           | n.t.         | >30               | n.t.         | n.t.            | n.t.         |

n.t.: not tested; NA: not active up to 200 µM.

*Mean of two experiments.

*Not active at 100 µM.

Mass prevents normal function of the protein. In our case, the different inhibitory activity of our compounds suggests that bulky and lipophilic molecules are required. However, docking studies should be performed on these methanethiosulfonate hybrids in order to deeply investigate their interaction with STAT3-SH2 domain.

Despite the excellent in vitro STAT3 inhibition of the thiosulfonate-drug hybrids, only three compounds, 1, 3, and 4 showed a moderate antiproliferative activity on HCT-116 cell line, whereas the other two potent compounds, 2 and 5, were inefficacious at concentration up to 100–200 µM. Since the STAT3 inhibition has been tested in a cell-free assay, the low cytotoxicity of the tested compounds could be related to their physicochemical properties, such as poor solubility and chemical stability in the culture medium, as well as on solubility and cell permeability, are needed.

The obtained results suggest that the methanethiosulfonate moiety represents a useful scaffold for the synthesis of new direct STAT3 inhibitors and the methanethiosulfonate drug hybrids described in this manuscript can be considered interesting hit compounds worthy of structural optimization.

Worth of note is the occasional isolation of a compound with an unusual sulfurated functionality (8) and endowed with valuable antiproliferative activity on HCT-116 cell line, deserving further investigation.

Acknowledgements
The authors acknowledge the Italian Ministero dell’Università e della Ricerca (MIUR), under the National Interest Research Projects framework (PRIN 20105YY2HL) for the financial support.

Disclosure statement
Prof. A. Sparatore is a coauthor of two patent applications describing two molecules studied in the manuscript. However these two patents have been abandoned several years ago and therefore she has no conflicts of interest to disclose.

Funding
Italian Ministero dell’Università e della Ricerca (MIUR) ([PRIN 20105YY2HL_007])

ORCID
Anna Sparatore <http://orcid.org/0000-0003-2135-2649>

References
1. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630–5.
2. Schindler C, Plumlee C. Interferons pen the JAK-STAT pathway. Semin Cell Dev Biol 2008;19:311–18.
3. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945–54.
4. Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995;269:81–3.
5. Masciocchi D, Gelain A, Villa S, et al. Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy. Future Med Chem 2011;3:567–97.
6. Keskin O, Gursoy A, Ma B, et al. Principles of protein-protein interactions: what are the preferred ways for proteins to interact? Chem Rev 2008;108:1225–44.
7. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007;450:1001–9.
8. Masciocchi D, Villa S, Meneghetti F, et al. Synthesis, structure-activity relationships and stereochemical investigations of new tricyclic pyridazine derivatives as potential STAT3 inhibitors. Med Chem Commun 2012;3:592–9.
9. Becker S, Groner B, Muller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 1998;394:145–51.
10. Zhao M, Jiang B, Gao FH. Small molecule inhibitors of STAT3 for cancer therapy. Curr Med Chem 2011;18:4012–18.
11. Mankan AK, Greten FR. Inhibiting signal transducer and activator of transcription 3: rationality and rationale of design inhibitors. Expert Opin Investig Drugs 2011;20:1263–75.
12. Siddiquie K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 2007;104:7391–6.
13. Fletcher S, Singh J, Zhang X, et al. Disruption of transcriptionally active Stat3 dimers with nonphosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. Chem Bio Chem 2009;10:1959–64.
14. Zhang X, Yue P, Page BD, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 represses human breast and lung cancer xenografts. Proc Natl Acad Sci USA 2012;109:9623–8.
15. Uehara Y, Mochizuki M, Matsuno K, et al. Novel high-throughput screening system for identifying STAT3-SH2 antagonists. Biochem Biophys Res Commun 2009;380:627–31.
16. Tian Y, Ye Y, Gao W, et al. Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway. Int J Colorectal Dis 2012;26:13–22.
17. Kim SR, Bae MK, Kim JY, et al. Aspirin induces apoptosis through the blockade of IL-6-STAT3 signaling pathway in human glioblastoma A172 cells. Biochem Biophys Res Commun 2009;387:342–7.
18. Nikitakis NG, Hamburger AW, Sauk JJ. The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells. Cancer Res 2002;62:1004–7.
19. Zhang X, Yue P, Page BD, et al. Orally bioavailable small-molecule inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 2007;104:7391–6.
20. Frantias J, Logan JG, Mollat P, et al. Hydrogen sulphide-releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo. British J Pharm 2012;165:1914–25.
21. Foong LY, You S, Jaikaran DC, et al. Development of a novel thiol reagent for probing ion channel structure: studies in a model system. Biochemistry 1997;36:1343.
22. Soppa S, Del Soldato P. Sulindac derivatives for treatment of cancer. WC 2006:134489; 2006.
23. Del Soldato P, Santus G, Soppa S. Thiosulfonate anti-inflammatory agents. WO2007101606(A1); 2007.
24. Boldyrev BG, Grivnak LM, Kolesnikova SA, et al. Thiosulfonic acids XV β-chloroethyl, β-hydroxy-ethyl, and carboxymethyl esters of thiosulfonic acids. Zhurnal Organicheskoi Khimi 1967;3:37–40.
25. Wang L, Clive Derrick LJ. Reagent for divalent sulfur protection: preparation of 4-methylbenzenesulfonofthioic acid, S-[(1,1-dimethylethyl)-dimethylsilyl]oxy[methyl] ester. Organ Synth 2013;90:10–24.
26. Harte AJ, Gunnlaugsson T. Synthesis of α-chloroamides in water. Tetrahedron Lett 2006;47:6321–4.
27. Sheldrick GM. SADABS area-detector absorption correction program. Madison (WI): Bruker AXS Inc.; 2000.
28. Altmare A, Burla MC, Camalli M, et al. SIR97: a new tool for crystal structure determination and refinement. J Appl Cryst 1999;32:115–19.
29. Sheldrick GM. A short history of SHELX-97. Acta Crystallogr A 2008;64:112–22.
30. Farrugia LJ. WinGX. Suite for small-molecule single-crystal crystallography. J Appl Cryst 1999;32:837–8.
31. Ferri N, Cazzaniga S, Mazzarella L, et al. Cytotoxic Effect of (1-methyl-1H-imidazol-2-yl)-methanamine and its derivatives in Pt(II) complexes on human carcinoma cell lines: a comparative study with cisplatin. Bioorg Med Chem 2013;21:2379–86.
32. Boldyrev BV, Vid LV, Khovalko LM, et al. Synthesis, structure, and properties of thiosulfonate esters bearing substituents in the ester group. Khim Seraorg Soedin, Soderzh Neftyakh Nefteprod 1972;9:282–6.
33. Verdine GL, Meena M, Iwamoto N, et al. Methods for the synthesis of functionalized nucleic acids. WC 2013012758(A1); 2013.
34. Fan LC, Teng HW, Shiu CW, et al. Pharmacological targeting of SHP-1-STAT3 signaling is a promising therapeutic approach for the treatment of colorectal cancer. Neoplasia 2015;17:687–96.
39. Akabas M, Stauffer D, Xu M, et al. Acetylcholine receptor channel structure probed in cysteine-substitution mutants. Science 1992;258:307–10.
40. Akabas MH, Kaufmann C, Archdeacon P, et al. Identification of acetylcholine receptor channel-lining residues in the entire M2 segment of the alpha subunit. Neuron 1994;13:919–27.
41. Akabas MH, Karlin A. Identification of acetylcholine receptor channel-lining residues in the M1 segment of the alpha-subunit. Biochemistry 1995;34:12496–500.
42. Chen JG, Liu-Chen S, Rudnick G. External cysteine residues in the serotonin transporter. Biochemistry 1997;36:1479–86.